skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination

Review

(1764) Views  (433) Full article downloads

Authors: Ijlal Uddin, Shakil Aslam

Published Date November 2010 Volume 2010:3 Pages 155 - 162
DOI: http://dx.doi.org/10.2147/IBPC.S6662

Ijlal Uddin, Shakil Aslam
Division of Nephrology and Hypertension, Georgetown University Hospital, Washington, District of Columbia, USA

Abstract: Hypertension is a major health problem worldwide and remains underdiagnosed and undertreated. Although public awareness and control of hypertension have improved over the last decade, only one-third of hypertensive patients achieve the rather conservative blood pressure (BP) goal of <140/90 mmHg. Most hypertensive patients require more than one drug for optimum BP control. Expert panels recommend use of combination therapy with two or more medications for Stage 2 and higher hypertension and in high-risk patients. However, the use of multiple drugs reduces patient compliance. Fixed-dose combination therapy helps improve patient compliance and thus achieve the target BP. Dose titration of the individual constituent drugs is recommended before switching to an equivalent fixed-dose combination. Randomized, controlled trials have shown that the fixed-dose combination of amlodipine–olmesartan medoxomil is more effective in lowering BP than monotherapy with either of these agents, with a similar side effect profile.

Keywords: hypertension, target blood pressure, compliance, amlodipine, olmesartan






Readers of this article also read:

De-stiffening drug therapy and blood pressure control
Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction
Optimal management of hypertension in elderly patients
Controversies on cosmetic outcomes in black women after breast conservation therapy: hyperperception or hyperpigmentation?
Olmesartan/amlodipine: a review of its use in the management of hypertension
Olmesartan medoxomil for the treatment of hypertension in children and adolescents
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University